» Articles » PMID: 19515028

Inhibitors in Factor IX Deficiency a Report of the ISTH-SSC International FIX Inhibitor Registry (1997-2006)

Overview
Journal Haemophilia
Specialty Hematology
Date 2009 Jun 12
PMID 19515028
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Haemophilia B is an X-linked disorder resulting in coagulation factor IX deficiency. Patients with severe deficiency (<1% factor IX activity) may have significant bleeding complications similar to patients with haemophilia A or factor VIII deficiency. The development of inhibitory antibodies to the missing coagulation factor is a major complication in patients with haemophilia. While the incidence of inhibitors in patients with haemophilia A is higher than that in haemophilia B, the occurrence of allergic and or anaphylactic reactions with the development of inhibitors is unique to haemophilia B patients. Since haemophilia B is a rare bleeding disorder and the incidence of inhibitors is an even rarer entity, a registry was established by Dr Indira Warrier under the auspices of the FVIII/FIX subcommittee of the International Society of Thrombosis and Haemostasis, to gather information on the occurrence and characteristics of patients with inhibitors and also the incidence of allergic and anaphylactic reactions in this group of patients. This is the first report from this registry and helps us to gather some insight on haemophilia B patients with inhibitors and complications related to inhibitor development and difficulties with immune tolerance.

Citing Articles

Successful immunosuppressive drug-free immune tolerance induction in hemophilia B with inhibitor and anaphylaxis to factor IX: A case report.

Palomo Bravo A, Prieto Bonilla R, Bardan Rebollar D, Lopez-Jaime F, Fernandez-Bello I Clin Case Rep. 2024; 12(8):e9312.

PMID: 39139619 PMC: 11319222. DOI: 10.1002/ccr3.9312.


Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B.

Lemons R, Wang M, Curtin J, Lepatan L, Male C, Peyvandi F TH Open. 2024; 8(1):e155-e163.

PMID: 38532939 PMC: 10965291. DOI: 10.1055/s-0044-1781466.


Factor IX administration in the skin primes inhibitor formation and sensitizes hemophilia B mice to systemic factor IX administration.

Sherman A, Bertolini T, Arisa S, Herzog R, Kaczmarek R Res Pract Thromb Haemost. 2024; 7(8):102248.

PMID: 38193070 PMC: 10772885. DOI: 10.1016/j.rpth.2023.102248.


Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia.

Tran D, Benson C, Boice J, Chitlur M, Dunn A, Escobar M Expert Rev Hematol. 2023; 16(sup1):19-37.

PMID: 36920859 PMC: 10020869. DOI: 10.1080/17474086.2023.2171981.


Updates on Novel Non-Replacement Drugs for Hemophilia.

Gualtierotti R, Pasca S, Ciavarella A, Arcudi S, Giachi A, Garagiola I Pharmaceuticals (Basel). 2022; 15(10).

PMID: 36297295 PMC: 9611302. DOI: 10.3390/ph15101183.